JP2020518243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518243A5 JP2020518243A5 JP2019559720A JP2019559720A JP2020518243A5 JP 2020518243 A5 JP2020518243 A5 JP 2020518243A5 JP 2019559720 A JP2019559720 A JP 2019559720A JP 2019559720 A JP2019559720 A JP 2019559720A JP 2020518243 A5 JP2020518243 A5 JP 2020518243A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequences
- light chain
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 775
- 238000006467 substitution reaction Methods 0.000 claims description 262
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 187
- 239000003153 chemical reaction reagent Substances 0.000 claims description 81
- 239000000427 antigen Substances 0.000 claims description 79
- 102000036639 antigens Human genes 0.000 claims description 79
- 108091007433 antigens Proteins 0.000 claims description 79
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 75
- 239000012634 fragment Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000021039 metastatic melanoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 230000003302 anti-idiotype Effects 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492533P | 2017-05-01 | 2017-05-01 | |
| US62/492,533 | 2017-05-01 | ||
| PCT/US2018/030350 WO2018204303A1 (en) | 2017-05-01 | 2018-05-01 | Methods and compositions relating to anti-pd1 antibody reagents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518243A JP2020518243A (ja) | 2020-06-25 |
| JP2020518243A5 true JP2020518243A5 (OSRAM) | 2021-05-13 |
| JP7257967B2 JP7257967B2 (ja) | 2023-04-14 |
Family
ID=64016985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559720A Active JP7257967B2 (ja) | 2017-05-01 | 2018-05-01 | 抗ｐｄ１抗体試薬に関する方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11427636B2 (OSRAM) |
| EP (1) | EP3619230A4 (OSRAM) |
| JP (1) | JP7257967B2 (OSRAM) |
| CN (1) | CN110809582B (OSRAM) |
| CA (1) | CA3060935A1 (OSRAM) |
| WO (1) | WO2018204303A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220175815A1 (en) | 2019-04-03 | 2022-06-09 | Orega Biotech | Combination therapies based on pd1 and il-17b inhibitors |
| EP4110810A1 (en) | 2020-02-28 | 2023-01-04 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
| US20240294641A1 (en) * | 2020-07-13 | 2024-09-05 | The Children's Medical Center Corporation | Novel anti-pd1 antibodies for inhibiting t-cell activity |
| EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622871A (en) | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
| US4135884A (en) | 1977-08-29 | 1979-01-23 | Shen James T | Gamma stick |
| US4305924A (en) | 1979-08-08 | 1981-12-15 | Ventrex Laboratories, Inc. | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system |
| US4444880A (en) | 1982-07-27 | 1984-04-24 | Syva Company | Periodate removal of ascorbate interference in dipsticks for immunoassays |
| ATE195022T1 (de) | 1987-04-27 | 2000-08-15 | Unilever Nv | Spezifische bindungstestverfahren |
| US4943522A (en) | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
| AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69229334T2 (de) | 1991-01-11 | 1999-12-16 | Quidel Corp., San Diego | Einstufiges querfluss analysenverfahren und ein darin verwendeter nichtsaugfähiger träger |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6824989B1 (en) | 2000-09-01 | 2004-11-30 | Upstate Biotechnology, Inc. | Recombinant monoclonal antibody to phosphotyrosine-containing proteins |
| US6565808B2 (en) | 2001-05-18 | 2003-05-20 | Acon Laboratories | Line test device and methods of use |
| US6902932B2 (en) | 2001-11-16 | 2005-06-07 | Tissue Regeneration, Inc. | Helically organized silk fibroin fiber bundles for matrices in tissue engineering |
| US20110009960A1 (en) | 2001-11-16 | 2011-01-13 | Allergan, Inc. | Prosthetic fabric structure |
| AU2003303082B2 (en) | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| CN1902227A (zh) | 2003-10-03 | 2007-01-24 | 布赖汉姆妇女医院 | Tim－3配体及其方法 |
| CA2603730A1 (en) | 2005-03-31 | 2006-10-05 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
| EP2418278A3 (en) * | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| CA2682701A1 (en) | 2007-03-20 | 2008-09-25 | Serica Technologies, Inc. | Prosthetic device and method of manufacturing the same |
| WO2010001617A1 (en) * | 2008-07-04 | 2010-01-07 | Ono Pharmaceutical Co., Ltd. | Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
| KR102702287B1 (ko) * | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| AU2013327116C1 (en) | 2012-10-02 | 2018-08-30 | Bristol-Myers Squibb Company | Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer |
| RS63571B9 (sr) * | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva |
| JP6479024B2 (ja) | 2014-01-24 | 2019-03-06 | ザ チルドレンズ メディカル センター コーポレーション | 抗体親和性の最適化のための高スループットマウスモデル |
| WO2015191491A1 (en) | 2014-06-09 | 2015-12-17 | The Procter & Gamble Company | Flushing dispensers for delivering a consistent consumer experience |
| CN105061597B (zh) | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| AU2016281641B2 (en) | 2015-06-23 | 2022-01-20 | Eureka Therapeutics, Inc. | Novel PD-1 immune modulating agents |
| BR112018000768A2 (pt) * | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| KR20180054824A (ko) | 2015-09-29 | 2018-05-24 | 셀진 코포레이션 | Pd-1 결합 단백질 및 이의 사용 방법 |
-
2018
- 2018-05-01 JP JP2019559720A patent/JP7257967B2/ja active Active
- 2018-05-01 CN CN201880043709.6A patent/CN110809582B/zh active Active
- 2018-05-01 US US16/608,275 patent/US11427636B2/en active Active
- 2018-05-01 EP EP18794360.0A patent/EP3619230A4/en active Pending
- 2018-05-01 CA CA3060935A patent/CA3060935A1/en active Pending
- 2018-05-01 WO PCT/US2018/030350 patent/WO2018204303A1/en not_active Ceased
-
2022
- 2022-07-21 US US17/870,010 patent/US20230192855A1/en active Granted
-
2025
- 2025-07-10 US US19/264,986 patent/US20250333511A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025160458A5 (OSRAM) | ||
| JP2019116474A5 (OSRAM) | ||
| JP2015172045A5 (OSRAM) | ||
| JP2019527553A5 (OSRAM) | ||
| JP2020518243A5 (OSRAM) | ||
| JP2019535670A5 (OSRAM) | ||
| JP2020533016A5 (OSRAM) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| JP2019532619A5 (OSRAM) | ||
| JP2008538289A5 (OSRAM) | ||
| JP2018516853A5 (OSRAM) | ||
| JP2020534830A5 (OSRAM) | ||
| JP2010513539A5 (OSRAM) | ||
| RU2019143101A (ru) | Новое анти-с-мет антитело и его применение | |
| JP2018522888A5 (OSRAM) | ||
| JPWO2021119193A5 (OSRAM) | ||
| JP2012519492A5 (OSRAM) | ||
| JP2024001073A5 (OSRAM) | ||
| JP2020518248A5 (OSRAM) | ||
| JPWO2020114480A5 (OSRAM) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| JPWO2019169212A5 (OSRAM) | ||
| JP2018513141A5 (OSRAM) | ||
| JPWO2022256563A5 (OSRAM) | ||
| JPWO2019175885A5 (OSRAM) |